No Data
Shattuck Labs' SL-325 Shows Positive Results in Inflammatory Bowel Disease
Shattuck Labs, Inc. to Present Novel Research on SL-325 at 2025 Crohn's and Colitis Congress
Stocks Mostly Rise Pre-Bell Ahead of Key Jobs Data; Asia, Europe Strong
Express News | Shattuck Labs Says As Of September 30, 2024, Cash And Cash Equivalents And Investments Were Approximately $90.1M That Is Expected To Fund Its Planned Operations Into 2027, Beyond Results From Its Phase 1 Trial Of SL-325
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025
Shattuck Labs Announces Participation in Upcoming December Conferences
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}